Ontology highlight
ABSTRACT:
SUBMITTER: Burger JA
PROVIDER: S-EPMC7214263 | biostudies-literature | 2020 Mar
REPOSITORIES: biostudies-literature
Burger Jan A JA Barr Paul M PM Robak Tadeusz T Owen Carolyn C Ghia Paolo P Tedeschi Alessandra A Bairey Osnat O Hillmen Peter P Coutre Steven E SE Devereux Stephen S Grosicki Sebastian S McCarthy Helen H Simpson David D Offner Fritz F Moreno Carol C Dai Sandra S Lal Indu I Dean James P JP Kipps Thomas J TJ
Leukemia 20191018 3
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0.5-0.8 mg/kg for ≤12 cycles. With a median (range) follow-up of 60 months (0.1-66), progression-free survival (PFS) and overall survival (OS) benefits for ibrutinib versus chlorambucil were sustained (PFS estimates at 5 years: 70% vs 12%; ...[more]